Abstract
Treatment-related neurotoxicity is a potentially life-threatening clinical condition that can represent a diagnostic challenge. Differentiating diagnoses between therapy-associated brain injury and recurrent disease can be difficult, and the immediate recognition of neurotoxicity is crucial to providing correct therapeutic management, ensuring damage reversibility. For these purposes, the knowledge of clinical timing and specific treatment protocols is extremely important for interpreting MRI patterns. Neuroradiologic findings are heterogeneous and sometimes overlapping, representing the compounding effect of the different treatments. Moreover, MRI patterns can be acute, subacute or delayed and involve different brain regions, depending on (1) the mechanism of action of the specific medication and (2) which brain regions are selectively vulnerable to specific toxic effects. This review illustrates the most common radiologic appearance of radiotherapy, chemotherapy and medication-associated brain injury in children, with special focus on the application of advanced MRI techniques (diffusion, perfusion and proton spectroscopy) in the diagnosis of the underlying processes leading to brain toxicity.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The term “treatment-related neurotoxicity” encompasses a heterogeneous group of clinical conditions in which the causative agent is an exogenous factor that may be identified in a specific medication or treatment protocol administered to the patient. Most literature reviews on this topic cover the adult population and only a few studies address the pediatric brain, with the most recent ones focusing on one specific medication-related toxicity, or on a specific group of patients [1–5].
With the recent advances in treatment protocols, especially in the fields of oncology and hematology, the recognition of neurotoxic patterns of injury in children is becoming a diagnostic challenge. In this population, differentiating diagnoses between therapy-associated brain injury and recurrent disease is crucial for the child’s therapeutic management and it requires prompt identification to help ensure damage reversibility and to avoid unnecessary aggressive treatments.
Specific medication-associated neurotoxicities sometimes manifest clinically as an urgent acute neurological condition, often requiring a prompt diagnostic and therapeutic management. This is especially true for neonates, where neurological symptoms are sometimes nonspecific, and the complex spectrum of endogenous toxic injuries, such as metabolic disorders, can confound the differential diagnosis [6].
Medical progress has led to an improvement of survival rates in children affected by either hematologic diseases or brain tumors, thus increasing the observation of delayed treatment-related effects [7]. A 4-fold increase in risk of severe health conditions has been reported in adult survivors of childhood leukemia compared to siblings of cancer survivors [8], and survivors treated with cranial radiotherapy seem to be at the greatest risk of metabolic, endocrine and neuro-cognitive dysfunction [9].
The known mechanisms of action of the most common therapeutic agents might explain the MRI patterns of toxicity-related injury because of the vulnerability of specific brain structures, the so-called topistic areas such as deep gray matter nuclei, which are often involved symmetrically and bilaterally in treatment-induced injury by various pharmacological agents [6, 10].
However when complex treatment protocols are applied, the radiologic picture can remain nonspecific, and only a combined knowledge of treatment-associated neurological adverse effects and of their clinical timing can help define possible diagnoses.
The purpose of this review is to describe specific clinical and radiologic scenarios of toxic encephalopathy, particularly the effects of radio-chemotherapy for solid tumors or myeloproliferative disorders, and of anti-epileptic and antibiotic medications. In this review we focus on the application of specific MRI techniques (diffusion, perfusion and proton spectroscopy).
In this paper we classify clinical conditions on the basis of their associated therapeutic agent (Fig. 1). However considering the heterogeneity of treatment protocols for pediatric oncologic-hematologic patients, all neurotoxic patterns should be considered as a part of possible overlapping scenarios, taking into account the possible compounding toxic effects of multiple therapeutic agents.
Radiotherapy
The effects of brain radiation depend on several factors, such as patient age, cumulative irradiation dose, type of irradiation (i.e. accelerated, conformal, hyperfractionated), duration of exposure, and concomitant antineoplastic or radiosensitizing agents. The classification of radiation effects on the brain is based on timing of the clinical presentation, and is divided into three main categories: acute (within 1–6 weeks), subacute or early delayed (3 weeks to 6 months) and chronic or late delayed (6 months to years) [2, 11]. Here we will only examine subacute and chronic effects, because acute effects are rare and often asymptomatic.
Early delayed effects
Early delayed effects represent the least understood injury from brain irradiation, and these effects occur between 3 weeks and several months after therapy. Transient demyelination is considered to be the underlying pathological process, and this is radiologically characterized by diffuse increased signal intensity on T2-weighted MR images within the white matter, more often periventricular (Fig. 2). These children are often clinically asymptomatic or present with mild attention deficit or sleepiness, and the clinical course is usually benign, with spontaneous resolution [2].
Late delayed effects — radiation necrosis
Late delayed effects of radiotherapy include a wide spectrum of brain injuries that mainly depend on the therapeutic approach (i.e. whole brain, stereotactic or 3-D conformal radiation) and on the variety of underlying physiopathological mechanisms involving vascular-related injury and direct effects on brain parenchyma, with a significant vulnerability of the white matter [12]. Consequently neuroimaging patterns are variable, ranging from the absence of visible macroscopic brain damage (usually associated with fractionated whole-brain irradiation) to frank focal areas of parenchymal necrosis that can occur 3–12 months after treatment (this more often occurs with administration of fractionated therapy in a selected region) [2, 11].
Radiation necrosis is defined as a severe focal tissue reaction characterized by blood–brain barrier disruption, and vasogenic edema and necrosis, with or without mass effect on MRI [12, 13]. The exact incidence and risk factors of radiation necrosis in children undergoing cranio-spinal irradiation remain undetermined because most reports on this condition refer to the adult population. However a large study on 236 children affected by central nervous system embryonal tumors treated with chemotherapy and cranio-spinal irradiation reported a cumulative incidence of radiation necrosis of about 3.7% at 5 years, with a higher incidence in patients affected by infratentorial tumors [14]. As reported in the literature, risk factors for radiation necrosis include clinical factors (tumor extent, surgical morbidity and postoperative central nervous system infection), percentage of infratentorial brain receiving radiation doses >50 Gy, and adjuvant chemotherapy. The clinical course of radiation necrosis may be variable, ranging from asymptomatic presentation to focal mild neurological symptoms, including seizures and cranial nerve deficits, to death in the most severe scenarios [14].
Although the diagnostic reference standard for radiation necrosis diagnosis is biopsy, MRI can assist in the diagnosis through a combination of conventional MR sequences with advanced techniques, such as (dynamic susceptibility contrast-enhanced) perfusion imaging and MR spectroscopy.
On conventional imaging the MR pattern of radiation necrosis usually shows, at a distance from the primary tumor site, a T2 hyperintense lesion with or without mass effect, surrounding vasogenic edema and heterogeneous contrast enhancement, described by Kumar et al. [15] as a “Swiss cheese” or “soap bubble” pattern (Fig. 3).
Perfusion images of radiation necrosis usually show absence of elevated perfusion on relative cerebral blood volume maps compared to recurrent tumor, suggesting ischemia-related changes and iatrogenic vasculopathy [13, 16, 17] (Fig. 3). However a clear differentiation between the entities is not always possible at radiologic examination because they sometimes coexist within the same lesion and standardized relative cerebral blood volume-cutoff values have not been established to clearly distinguish the two entities [18–20]. MR spectroscopy is another tool to examine the suspected necrosis; it demonstrates high lipid and lactate peaks with variable concentrations of choline, N-acetylaspartate and creatine [21].
However to differentiate radiation necrosis from recurrent tumor, a thorough evaluation of serial changes on follow-up examinations is also crucial because the resolution of necrotic changes may be a long process, entailing various combinations of reduction or enlargement of necrotic lesions before complete stabilization [14].
In the last decade an increasing number of hospitals worldwide have installed systems for proton beam therapy. The main advantage of this technique over conventional photon therapy is the reduction of the dose to normal tissues, which can be achieved through more precise control of the proton beam depth. Specific guidelines for the use of proton therapy in pediatric central nervous system tumors have been developed but its use in clinical practice is still limited because of its insufficient availability [22]. For these reasons studies of possible proton-therapy-induced neurotoxicity are still scarce.
Late delayed effects — other
Children treated with cranial irradiation develop a higher risk of hormonal disturbances as a result of an impaired hypothalamic-pituitary axis, as well as brain atrophy, calcifications, vascular malformations and secondary malignancies [5].
Secondary cerebral cavernous malformations have been reported as the most frequent MRI abnormalities in childhood leukemia survivors treated with cranial radiotherapy, with an incidence of 57% [23]. Several studies have described a higher incidence of cerebral cavernous malformations in the periphery of the radiation field, suggesting a more effective role of low radiation doses compared to higher doses in the genesis of these secondary vascular malformations [24]. Cerebral cavernous malformations detection increases with the acquisition of T2*-weighted gradient-echo MR sequences and susceptibility-weighted images, which have a higher sensitivity in identifying susceptibility effects of blood product deposits [25] (Fig. 4). Clinical presentations of cerebral cavernous malformations can be heterogeneous, varying from asymptomatic conditions to seizures or rare fatal hemorrhage, which is believed to occur with a higher incidence when cerebral cavernous malformations are located in deep cerebral structures [26]. However the differences in clinical history between radiation-induced cerebral cavernous malformations and isolated ones have not been fully elucidated: some studies have attributed to the former a lower incidence of seizures, while others have reported in the same group a higher occurrence of hemorrhagic events [27, 28]. Therefore surgical treatment should be considered only in select cases presenting with refractory seizures, and recurrent hemorrhage or neurological deterioration [26].
Mineralizing microangiopathy is a well-known form of radiation-induced damage, resulting from injury to small- and medium-size vessels with hyalinization, fibrinoid necrosis, endothelial proliferation and calcium deposition. The best diagnostic radiologic tool for mineralizing microangiopathy is CT, which shows calcium deposition mainly localized in the basal ganglia and subcortical white matter [4, 29] (Fig. 5).
Secondary brain tumors are a severe complication of cranial irradiation and have been reported with a variable cumulative incidence ranging from 4% to 15% depending on the duration of follow-up. These lesions are mainly represented by meningiomas, which, compared to the primary tumors, are reported to have a more aggressive course and a higher incidence of recurrence [30, 31].
Chemotherapy
Chemotherapy-related neurotoxicity in children is a rare condition, and it often presents clinically with acute severe neurological symptoms. The main chemotherapeutic agents associated with central nervous system toxic effects are methotrexate, cytarabine, vincristine, asparaginase and corticosteroids [5]. Clinical and radiologic patterns can be extremely heterogeneous because of the vast variety and combinations of medications. However, considering their clinical relevance and prevalence, we focus here on the most commonly observed forms of toxic leukoencephalopathy associated with chemotherapeutic agent administration or immunosuppression, namely posterior reversible encephalopathy syndrome and acute toxic leukoencephalopathy.
Posterior reversible encephalopathy syndrome
Posterior reversible encephalopathy syndrome (PRES) is a clinical condition characterized by headache, seizures, visual disorders and altered mental status. In children, PRES is not a rare disorder and it can develop during oncologic treatment for hematologic diseases and solid tumors, especially during the induction phase of treatment or, more often, during transplantation-associated immunosuppressive therapy (cyclosporine and tacrolimus) [32, 33]. Several pathological conditions in pediatric patients with PRES have been described, namely infections or sepsis, post-transplantation immunosuppressive therapy, and post-chemotherapy and autoimmune disorders [33].
The exact physiopathogenic mechanism of the disorder is not fully understood. Two main theories have been proposed and both are supported by contrasting findings in the literature. In the original theory, cerebral hypoperfusion with subsequent vasogenic edema is the endpoint of a vasoconstrictive response that is thought to be an attempt to compensate for evolving hypertension. A more recent theory suggests that severe hypertension exceeding vascular autoregulation limits is the pivotal event leading to hyperperfusion with subsequent blood–brain barrier injury and brain edema [34]. This hypothesis has been recently supported by a report on postoperative PRES in a child treated for posterior fossa tumor; in this case PRES was caused by intraoperative hypertension following brainstem manipulation [35].
In case of treatment with cyclosporine, the pathogenic mechanism seems to depend on direct endothelial damage caused by the specific therapeutic agent that determines a cytokine storm with subsequent increased systemic blood pressure, induced sympathetic autoregulatory vasoconstriction, and breakdown of physiological autoregulation. In turn, these events lead to cerebral hypoperfusion, blood–brain barrier damage and vasogenic edema [34].
Posterior territory involvement is more common than anterior territory involvement. This is thought to be related to sparse sympathetic innervation of the vertebrobasilar circulation, which makes this territory more vulnerable to altered autoregulation response in PRES [36].
In the pediatric setting, PRES is often associated with immunosuppressive agents, like cyclosporine and tacrolimus, for allogenic bone marrow transplantation in children affected by hematopoietic malignancies [37]. Cyclosporine neurotoxicity is considered to occur in 7–9% of all allogenic bone marrow transplantation [32], while tacrolimus-related PRES is responsible for 1.6% of all PRES cases with a clinical onset after 61 days from treatment initiation [36]. Both neurotoxic syndromes seem to be unrelated to dose and a prompt treatment discontinuation is usually followed by clinical improvement.
In most children with PRES, hypertension has been identified as a predisposing condition often triggered by corticosteroid therapy or renal dysfunction. However, 20–40% of patients are normotensive at the time of clinical onset [37]. Other triggers, especially identified on leukemic patients, include tumor lysis syndrome, which may induce acute renal failure and electrolytic disequilibrium, leading to PRES development.
The MRI pattern is usually characterized by vasogenic edema with increased signal on T2-weighted images, and apparent diffusion coefficient maps without contrast enhancement. Signal alterations most commonly affect parietal and occipital lobes, but frontal lobes and cerebellum can also be involved, especially in children (Fig. 6) [38]. Therefore recent studies tend to consider PRES a misnomer because this syndrome is not always posterior nor always reversible. In both children and adults, hemorrhage and diffusion restriction might be observed and are often related to irreversible brain damage; on the other hand, contrast enhancement caused by blood–brain barrier breakdown is more commonly reported in the pediatric population [37, 38].
Acute toxic leukoencephalopathy
Acute toxic leukoencephalopathy is a form of white matter damage with acute neurological symptoms that can be caused by a wide spectrum of exogenous or endogenous toxic insults, ranging from chemotherapeutic agents (e.g., methotrexate, 5-fluorouracil, fludarabine) and immunosuppressive agents (e.g., cyclosporine, tacrolimus) to environmental toxins (e.g., carbon monoxide) and congenital metabolic disorders. Clinical scenarios vary from completely reversible symptoms to severe neurological damage, depending on the primary cause of the acute toxic leukoencephalopathy, with hypoxic–ischemic injury and endogenous metabolic disorders being associated with neurologic sequelae, and exogenous toxins being more often related to reversible clinical conditions [39, 40].
However, even though the clinical prognosis of acute toxic leukoencephalopathy is extremely heterogeneous, the underlying causes share two common features: the combination of acute neurological symptoms with a common MRI pattern of disease.
The MRI pattern is characterized by symmetrical and bilateral signal alterations in the white matter of centrum semiovale and corona radiata, which are hyperintense on T2-weighted sequences. This pattern typically shows restricted diffusion on early imaging, suggesting cytotoxic edema, and it usually lacks contrast enhancement (Fig. 7).
Because acute toxic leukoencephalopathy is rarely biopsied as a result of its clinical reversibility, the pathogenesis is poorly understood and probably multifactorial. In the treatment-related setting, the suggested mechanisms of toxicity include direct microvasculature damage or an excitotoxic effect on the tissue [41, 42].
The main differential diagnosis of acute toxic leukoencephalopathy in the pediatric population includes PRES because of its acute neurological-related manifestations and common clinical oncologic–hematologic setting.
Compared to PRES, acute toxic leukoencephalopathy has similar clinical symptoms at onset, mainly consisting of headache, seizures, visual impairment and altered cognition, but, differently from PRES, in acute toxic leukoencephalopathy cognitive dysfunction might be more severe. Moreover MRI lesion distribution is often different in the two disorders, being more commonly located in the cortex or subcortical white matter in PRES and in the deep white matter in acute toxic leukoencephalopathy [3]. Finally, the prognosis of acute toxic leukoencephalopathy is slightly worse than that of PRES, and the clinical severity is most commonly related to the extent of MRI findings [43].
Concomitant chemo/radiotherapy
The risk of developing central nervous system complications increases when chemotherapy is associated with brain irradiation, suggesting a possible additive role of chemotherapeutic agents to radiation in determining a toxic effect.
In the last few years, new therapeutic protocols for the treatment of malignant pediatric brain tumors, such as primitive neuroectodermal tumors and medulloblastomas, have been introduced to improve overall survival. The recently introduced therapeutic strategies for metastatic medulloblastomas combine the use of high-dose chemotherapy and hyperfractionated accelerated radiotherapy with myeloablative doses of thiotepa in select high-risk cases [44].
The improvement of overall survival in metastatic medulloblastomas treated with the aforementioned protocol (often referred to as the Milan protocol) is still a matter of debate because only single-center studies with conflicting results are available [44, 45]. However these therapeutic strategies, and especially the combination of radiotherapy with thiotepa, have increased the observation of different patterns of neurotoxicity, namely transient white matter lesions (also referred to as transient focal enhancing lesions) and diffuse white matter injury [46, 47].
Transient focal enhancing lesions
Transient focal enhancing lesions have been recently observed in patients treated with radiotherapy (especially hyperfractionated accelerated radiotherapy) and high-dose chemotherapy with myeloablative doses of thiotepa for the treatment of primary malignant central nervous system tumors, and have been associated with both symptomatic and asymptomatic clinical conditions [46–48]. Transient focal enhancing lesions can occur about 7–8 months after chemotherapy/radiotherapy initiation, either in supra- or infratentorial regions, but they most frequently involve the pons and cerebellum in locations remote from the primary tumor site [47].
MRI appearance consists of focal millimetric lesions isointense to gray matter on T1-weighted sequences and hyperintense on T2-weighted sequences, almost always showing avid nodular (described as “snowflakes”) or curvilinear contrast enhancement [46].
Diffusion-weighted imaging can be helpful to differentiate transient focal enhancing lesions from recurrent disease, showing increased diffusion in transient focal enhancing lesions compared to recurrence, and diffusion restriction in recurrence [47]. However this is not always true because diffusion restriction has also been described in transient focal enhancing lesions. Moreover, not all medulloblastomas show low apparent diffusion coefficient values [47]. These considerations are even more important when the two conditions coexist.
In the majority of patients, these lesions resolve spontaneously within a variable period of time, but they may also remain stable or progress to atrophy or radiation necrosis [46] (Fig. 8). The pathogenesis of this neurotoxic phenomenon is poorly understood, but authors suggest that a compounding toxic effect of radiation with chemotherapy or thiotepa, together with an immune reaction after autologous stem cell transplant, might play a pivotal role [46]. The few pathologically proven samples available have shown the presence of diffuse demyelination within the white matter lesions, without evidence of significant inflammation [48].
Diffuse white matter injury
Concomitant administration of chemotherapy and irradiation for both solid and hematologic central nervous system tumors has been associated with a diffuse form of white matter injury, often referred to as leukoencephalopathy. About 80% of patients treated for acute lymphoblastic leukemia develop leukoencephalopathy, and the improved overall survival of patients affected by primary brain tumors has led to a higher recognition of this entity in this category of patients [7].
Risk factors associated with the development of leukoencephalopathy are higher radiation doses, methotrexate administration, and younger age of the patient, the last of which is probably related to a great vulnerability of the myelinating brain to toxicity [7, 49].
Neurological signs vary from subtle progressive cognitive deterioration to severe neurological disturbances. Similarly, MRI pattern is characterized by transient soft non-enhancing periventricular T2-hyperintensities to slowly progressive confluent analogous signal alterations, which follow a centrifugal pattern from periventricular regions to subcortical white matter, sparing subcortical U-fibers with absent or marked enhancement [1] (Fig. 9).
Several studies have identified fractional anisotropy maps derived from diffusion tensor imaging as a promising tool to investigate relations between white matter damage and cognitive impairment associated with treatment-related toxicity. Studies on survivors of acute lymphoblastic leukemia and medulloblastomas found (1) significant differences between fractional anisotropy values in normal-appearing white matter tracts of patients compared to controls and (2) a statistical correlation between fractional anisotropy value abnormalities and neurocognitive test outcomes, suggesting an impaired microstructural anatomical substrate to altered cognition [50–53].
Recently with the introduction of the aforementioned therapeutic strategies developed for high-risk malignant central nervous system tumors, treatment-induced diffuse leukoencephalopathy has been reported, with subacute rather than chronic onset associated with devastating neurological deficits. This condition has been reported with conflicting and in some cases warning percentages, especially in patients treated with thiotepa after hyperfractionated accelerated radiotherapy, suggesting a possible compounding effect of these therapies and raising the need for international multicenter clinical trials [45, 47, 54, 55] (Fig. 10).
Specific medication-related neurotoxicities
Methotrexate-induced neurotoxicity
Methotrexate is a component of chemotherapy for acute lymphoblastic leukemia and has been recognized to be the main component responsible for acute therapy-induced neurotoxicity in children with acute lymphoblastic leukemia. Methotrexate inhibits cell replication by blocking the enzyme dihydrofolate reductase, thus preventing the conversion of folic acid to tetrahydrofolic acid. As it crosses the blood–brain barrier, it can be administered both intravenously and via intrathecal route to treat the disease and prevent recurrence in the central nervous system. The exact pathophysiological mechanisms of methotrexate-induced neurotoxicity are unclear, but both indirect (accumulation of adenosine and homocysteine) and direct (excitatory effect on N-methyl-D-aspartate receptors) toxic effects on brain tissue have been proposed [56]. Risk factors for toxicity include high-dose chemotherapy, intrathecal administration, associated brain radiation and young age [3].
Brain alterations related to methotrexate administration have been described as acute or chronic. The former are clinically characterized by stroke-like symptoms as aphasia, sensory deficits, ataxia and seizures, and have been more related to intrathecal administration [57]. On the other hand, chronic neurological effects, mainly consisting of cognitive disorders, have been more frequently associated with methotrexate intravenous injections [58, 59]. These differences are also reflected in the neuroradiologic findings. The neuroradiologic picture of acute methotrexate-induced toxicity is similar to that of acute toxic leukoencephalopathy (and these sometimes overlap), with bilateral hyperintensities on T2-weighted MR sequences within periventricular white matter and centrum semiovale, associated with foci of diffusion restriction in early phases, representing cytotoxic edema, probably the result of a direct neurotoxic effect of methotrexate on the cells (Fig. 11) [3, 57]. However regions of diffusion restriction after intrathecal administration of methotrexate are not necessarily associated with irreversible brain damage and cell death and, therefore, they should not worsen the prognosis [56, 57].
If compared to acute toxic leukoencephalopathy resulting from other medications, the neurotoxicity pattern related to methotrexate administration often shows involvement of the splenium of the corpus callosum (Fig. 11) [60]. After intravenous administration of methotrexate, the MRI pattern of neurotoxicity corresponds to a diffuse periventricular leukoencephalopathy, which is highly nonspecific, as already shown in concomitant chemotherapy- and radiotherapy-related findings. This pattern has been reported to occur in 9–33% of patients treated for acute lymphoblastic leukemia and intravenous methotrexate and never exposed to radiotherapy. However radiologic findings (in terms of extent and intensity of leukoencephalopathy) have shown a decrease over time by about 1.5 years after completion of therapy, suggesting a partial reversibility of the drug-related effects on cerebral white matter [58, 59].
L-asparaginase-related complications
L-asparaginase is an important component of remission-induction therapy in children affected by acute lymphoblastic leukemia. By hydrolyzing asparagine to aspartic acid and ammonia, L-asparaginase acts on different proteins throughout the body and can also affect the blood coagulation system. The most serious brain complications related to this treatment are indeed hemorrhagic and thromboembolic events resulting from L-asparaginase-induced alterations in the clotting system [61, 62].
Cerebral venous thrombosis is an acute complication of the induction phase of leukemia treatment with L-asparaginase that is observed in about 30% of acute neurologic adverse events in children with acute lymphoblastic leukemia. Clinical suspicion of cerebral venous thrombosis can be guided by the presence of seizures, focal neurological deficits and features of raised intracranial pressure, including headache, vomiting and altered mental status [62]. However because clinical manifestations of cerebral venous thrombosis can be extremely variable, it is mandatory, in order to avoid missing the diagnosis, to evaluate the patient with urgent neuroimaging techniques (CT or MRI), with protocols specifically focused on typical signs of cerebral venous thrombosis.
In the event of sinus thrombosis, non-contrast CT can detect the hyperdensity of the thrombosed sinus. Contrast-enhanced CT might show a characteristic sign called “empty delta,” which is represented by enhancement surrounding the thrombosed sinus. However contrast-enhanced CT does not exceed a sensitivity of 60% in the diagnosis of cerebral venous thrombosis [62].
MRI is much more sensitive than CT in evaluating cerebral venous thrombosis, especially for the detection of early parenchymal infarction. On conventional images, the thrombus is mainly identified on T1-weighted images, especially in the subacute phase, demonstrating a hyperintense signal, whereas T2*-weighted gradient echo sequence might help in the identification of the thrombosed vein, especially in isolated cortical vein thrombosis cases. The demonstration of a flow void in MR venography is considered to be the most specific diagnostic sign of cerebral venous thrombosis, with a high sensitivity even in the acute phase of thrombosis, during which the main MR characteristics are isointensity on T1-weighted and low signal intensity on T2-weighted imaging [63, 64].
Vigabatrin-associated neurotoxicity
Vigabatrin is a selective and irreversible γ-aminobutyric acid transaminase inhibitor used as an anti-epileptic drug for the treatment of infantile spasms and refractory complex partial seizures in children and adults. The safety of vigabatrin was first challenged in a report of white matter anomalies from preclinical studies in rats, showing cellular vacuolation and intramyelic edema, but these results have not been demonstrated in humans [64, 65].
In young children with infantile spasms, high-dose vigabatrin administration might be associated with neurotoxicity, with transient asymptomatic MRI abnormalities in 10–20% of treated patients [64]. These alterations have been related mainly to vigabatrin administration rather than the underlying epileptic condition [66], and might be related to a γ-aminobutyric-acid-induced excitotoxicity mechanism, which provokes transient failure of the sodium/potassium adenosine triphosphate pump or possibly transient cellular vacuolation, a result of depolarizing effects [65].
The MR pattern is characterized by the preferential involvement of deep brain structures, which, like the metronidazole-associated toxicity described in the next section, mainly affects the basal ganglia, corpus callosum, dentate nuclei and brainstem; more rarely, cerebellum and thalamus are affected. This distribution likely reflects a selective vulnerability to vigabatrin related to region-specific γ-aminobutyric acid metabolism [65].
On conventional imaging, brain lesions show high signal intensity on T2-weighted images, with restricted diffusion on diffusion-weighted imaging and apparent diffusion coefficient maps, a consequence of cytotoxic edema (Fig. 12). Usually these anomalies are transient, showing spontaneous resolution (without medication discontinuation) in about 12 months, and they have not been associated with any clinical sequelae, often remaining asymptomatic and with a good seizure control [3, 64, 65]. Consequently when toxic-related brain alterations are detected, vigabatrin administration can be continued under MRI surveillance.
Metronidazole neurotoxicity
Metronidazole is an antibiotic agent often used for the treatment of aerobic and protozoal infections. Therapy with high doses (more than 2 g per day) and for long periods, or in children with hepatic failure, can induce neurotoxicity, the pathogenic mechanism of which is still not entirely understood [67, 68].
Metronidazole neurotoxicity is clinically characterized by severe neurological symptoms such as cerebellar signs (ataxia, dysarthria), peripheral neuropathy, seizures and encephalopathy. MR anomalies involve deep brain structures such as cerebellar dentate nuclei, splenium of the corpus callosum, basal ganglia and brainstem [69]. The dentate nuclei involvement in children might depend on several pathological conditions (e.g., metabolic conditions, mitochondrial disorders, neurofibromatosis) that have to be taken into account in the differential diagnosis [70].
The most representative MR findings are T2 hyperintensities associated with high signal on apparent diffusion coefficient maps, indicating increased diffusion, which reflects vasogenic edema. However diffusion restriction has also been observed in acute phases, particularly within red nuclei and periaqueductal gray, showing the so-called “giant panda face with bright eyes” sign [70].
Some studies report that vasogenic edema predominates in cerebellar, midbrain and brainstem lesions, whereas cytotoxic edema prevails at supratentorial sites such as the corpus callosum and subcortical white matter [69]. MR spectroscopy abnormalities have also been described in association with metronidazole use, namely the presence of a nonspecific elevated lactate peak. Typically complete resolution of neural tissue alterations on MR imaging is observed several weeks after discontinuing therapy.
Hepatic encephalopathy
Treatment-related liver toxicity is not an infrequent condition in children, and it may indirectly lead to subsequent neurological effects. The pathogenesis of hepatic encephalopathy might be explained by blood-accumulation of several compounds — namely manganese and ammonia — that are normally metabolized by a healthy liver but accumulate in cases of liver dysfunction. Manganese can be found in all human tissues and is metabolized by the liver and excreted via the hepatobiliary route. In children with liver failure, manganese concentration increases in plasma and enters the brain through the blood–brain barrier, developing a neurotoxic effect. Manganese neural deposition in children has been associated with food supplements, water pollution and parenteral nutrition (direct deposition), and can also be related to pharmacological therapy, depending on liver toxicity (indirect deposition) [71]. The clinical correlate varies from an asymptomatic condition to neurological symptoms including movement disorders and seizures, some of which might resolve after discontinuation of manganese supplementation or restoration of normal liver function [72, 73].
The primary brain region involved in manganese deposition is the basal ganglia, especially within the globus pallidus and striatum, which might show symmetrical hyperintensities on unenhanced T1-weighted MR sequences because of manganese’s paramagnetic properties [72]. In case of liver failure, elevated levels of circulating ammonia can be detected in blood and are sometimes deposited in brain tissue, passing through the blood–brain barrier. This deposit can induce high glutamine levels and astrocytes swelling as a result of ammonia detoxification, finally leading to brain edema and increased intracranial pressure. In cases of hepatic encephalopathy, MR spectroscopy studies show an increase in the glutamine/glutamate signal intensity accompanied by myoinositol depletion and a decrease in the choline signal intensity, a result of ammonia metabolic pathway (Fig. 13) [71].
Conclusion
Neurotoxicity in children can be the result of many disease treatments, often leading to life-threatening clinical conditions. Considering the complexity of therapeutic protocols used in the pediatric oncologic–hematologic population, and the individual susceptibility to neurotoxic damage, it is extremely important to consider the suggested categories of neurotoxic conditions as a continuous spectrum of overlapping clinical and radiologic scenarios, and not as categories confined in a rigid scheme. The knowledge of treatment protocols, modalities of administration and therapeutic timelines with special attention to specific MRI patterns of neurotoxicity might be conducive to prompt recognition and a multidisciplinary approach encompassing continual communication among oncologists, radiotherapists and radiologists, all of which is of paramount importance for the child’s correct diagnostic and therapeutic management.
References
Pružincová Ľ, Šteňo J, Srbecký M et al (2009) MR imaging of late radiation therapy- and chemotherapy-induced injury: a pictorial essay. Eur Radiol 19:2716–2727
Ball WS Jr, Prenger EC, Ballard ET (1992) Neurotoxicity of radio/chemotherapy in children: pathologic and MR correlation. AJNR Am J Neuroradiol 13:761–776
Iyer RS, Chaturvedi A, Pruthiet S et al (2011) Medication neurotoxicity in children. Pediatr Radiol 41:1455–1464
Vázquez E, Lucaya J, Castellote A et al (2002) Neuroimaging in pediatric leukemia and lymphoma: differential diagnosis. Radiographics 22:1411–1428
Vázquez E, Delgado I, Sánchez-Montañez A et al (2011) Side effects of oncologic therapies in the pediatric central nervous system: update on neuroimaging findings. Radiographics 31:1123–1139
Valk J, Van der Knaap S (1992) Toxic encephalopathy. AJNR Am J Neuroradiol 13:747–760
Reddick WE, Taghipour DJ, Glass JO et al (2014) Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers. Pediatr Blood Cancer 61:1074–1079
Oeffinger K, Mertens A, Sklar C et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582
Hudson MM, Ness KK, Gurney JG et al (2013) Clinical ascertainment health outcomes among adults treated for childhood cancer. JAMA 309:2371–2381
Quattrocchi CC, Errante Y, Rossi Espagnet MC (2016) Magnetic resonance imaging differential diagnosis of brainstem lesions in children. World J Radiol 8:1–20
Greene-Schloesser D, Robbins ME, Peiffer AM et al (2012) Radiation-induced brain injury: a review. Front Oncol 19:2–73
Perry A, Schmidt RE (2006) Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 111:197–212
O’Brien BJ, Colen RR (2014) Post-treatment imaging changes in primary brain tumors. Curr Oncol Rep 16:397
Murphy ES, Merchant TE, Wu S et al (2012) Necrosis after craniospinal irradiation: results from a prospective series of children with central nervous system embryonal tumors. Int J Radiat Oncol Biol Phys 83:e655–e660
Kumar AJ, Leeds NE, Fuller GN et al (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377–384
Poussaint TY, Rodriguez D (2006) Advanced neuroimaging of pediatric brain tumors: MR diffusion, MR perfusion, and MR spectroscopy. Neuroimaging Clin N Am 16:169–192
Ball WS, Holland SK (2001) Perfusion imaging in the pediatric patient. Magn Reson Imaging Clin N Am 9:207–230
Bangiyev L, Rossi Espagnet MC, Young R (2014) Adult brain tumor imaging: state of the art. Semin Roentgenol 49:39–52
Sugahara T, Korogi Y, Tomiguchi S et al (2000) Post-therapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 21:901–909
Hu LS, Baxter LC, Smith KA et al (2009) Relative cerebral blood volume values to differentiate high-grade glioma recurrence from post-treatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 30:552–558
Verma N, Cowperthwaite MC, Burnett MG et al (2013) Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol 15:515–534
Merchant T, Farr JB (2014) Proton beam therapy: a fad or a new standard of care. Curr Opin Pediatr 26:3–8
Faraci M, Morana G, Bagnasco F et al (2011) Magnetic resonance imaging in childhood leukemia survivors treated with cranial radiotherapy: a cross sectional, single center study. Pediatr Blood Cancer 57:240–246
Koike T, Yanagimachi N, Ishiguro H et al (2012) High incidence of radiation-induced cavernous hemangioma in long-term survivors who underwent hematopoietic stem cell transplantation with radiation therapy during childhood or adolescence. Biol Blood Marrow Transplant 18:1090–1098
Huisman TAGM, Singhi S, Pinto PS (2010) Non-invasive imaging of intracranial pediatric vascular lesions. Childs Nerv Syst 26:1275–1295
Di Giannatale A, Morana G, Rossi A et al (2014) Natural history of cavernous malformations in children with brain tumors treated with radiotherapy and chemotherapy. J Neuro Oncol 117:311–320
Nimjee SM, Powers CJ, Bulsara KR (2004) Review of the literature on de novo formation of cavernous malformations of the central nervous system after radiation therapy. Neurosurg Focus 21:e4
Acciarri N, Galassi E, Giulioni M et al (2009) Cavernous malformations of the central nervous system in the pediatric age group. Pediatr Neurosurg 45:81–104
Chen CY, Zimmerman RA, Faro S et al (1996) Childhood leukemia: central nervous system abnormalities during and after treatment. AJNR Am J Neuroradiol 17:295–310
Löning L, Zimmermann M, Reiter A et al (2000) Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 95:2770–2775
Hijiya N, Hudson MM, Lensing S et al (2007) Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297:1207–1215
Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 29:1036–1042
Morris EB, Laningham FH, Sandlund JT et al (2007) Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer 48:152–159
Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 29:1043–1049
Patel AJ, Fox BD, Fulkerson DH et al (2010) Posterior reversible encephalopathy syndrome during posterior fossa tumor resection in a child. J Neurosurg Pediatr 6:377–380
Hodnett P, Coyle J, O’Regan K et al (2009) PRES (posterior reversible encephalopathy syndrome), a rare complication of tacrolimus therapy. Emerg Radiol 16:493–496
Donmez FY, Guleryuz P, Agildere M (2014) MRI findings in childhood PRES: what is different than the adults? Clin Neuroradiol 26:209–213
McKinney AM, Short J, Truwit CL et al (2007) Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 189:904–912
McKinney AM, Kieffer SA, Paylor RT et al (2009) Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol 193:192–206
Filley CM, Kleinschmidt-DeMasters BK (2001) Toxic leukoencephalopathy. N Engl J Med 345:425–432
Akiba T, Okeda R, Tajima T (1996) Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture. Acta Neuropathol 92:8–13
Wijdicks EF (2001) Neurotoxicity of immunosuppressive drugs. Liver Transpl 7:937–942
Beitinjaneh A, McKinney AM, Cao Q et al (2011) Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 17:300–308
Gandola L, Massimino M, Cefalo G et al (2009) Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 27:566–571
Vivekanandan S, Breene R, Ramanujachar R et al (2015) The UK experience of a treatment strategy for pediatric metastatic medulloblastoma comprising intensive induction chemotherapy, hyperfractionated accelerated radiotherapy and response directed high dose myeloablative chemotherapy or maintenance chemotherapy (Milan strategy). Pediatr Blood Cancer 62:2132–2139
Spreafico F, Gandola L, Marchianò A et al (2008) Brain magnetic resonance imaging after high-dose chemotherapy and radiotherapy for childhood brain. Int J Radiat Oncol Biol Phys 70:1011–1019
Thust SC, Blanco E, Michalski AJ et al (2014) MRI abnormalities in children following sequential chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa for high-risk primitive neuroectodermal tumours of the central nervous system. J Med Imaging Radiat Oncol 58:683–690
Fouladi M, Chintaqumpala M, Laningham FH et al (2004) White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 22:4551–4560
Dietrich U, Wanke I, Mueller T et al (2001) White matter disease in children treated for malignant brain tumors. Childs Nerv Syst 17:731–738
Edelmann MN, Krull KR, Liu W et al (2014) Diffusion tensor imaging and neurocognition in survivors of childhood acute lymphoblastic leukaemia. Brain 137:2973–2983
Khong PL, Leung LH, Chan GC et al (2005) White matter anisotropy in childhood medulloblastoma survivors: association with neurotoxicity risk factors. Radiology 236:647–652
Khong PL, Leung LH, Fung AS et al (2006) White matter anisotropy in post-treatment childhood cancer survivors: preliminary evidence of association with neurocognitive function. J Clin Oncol 24:884–890
Palmer SL, Reddick WE, Glass JO et al (2010) Regional white matter anisotropy and reading ability in patients treated for pediatric embryonal tumors. Brain Imaging Behav 4:132–140
Massimino M, Spreafico F, Pignoli E et al (2016) Comment on: The UK experience of a treatment strategy for pediatric metastatic medulloblastoma comprising intensive induction chemotherapy, hyperfractionated accelerated radiotherapy and response directed high-dose myeloablative chemotherapy or maintenance chemotherapy (Milan strategy). Pediatr Blood Cancer 63:1123–1124
Vivekanandan S (2016) Reply to comment on: The UK experience of a treatment strategy for pediatric metastatic medulloblastoma comprising intensive induction chemotherapy, hyperfractionated accelerated radiotherapy, and response-directed high-dose myeloablative chemotherapy or maintenance chemotherapy (Milan strategy). Pediatr Blood Cancer 63:1125–1126
Fisher MJ, Khademian ZP, Simon EM et al (2005) Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. AJNR Am J Neuroradiol 26:1686–1689
Rollins N, Winick N, Bash R et al (2004) Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 25:1688–1695
Reddick WE, Glass JO, Helton KJ et al (2005) Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 26:1263–1269
Reddick WE, Glass JO, Helton KJ et al (2005) A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. AJNR Am J Neuroradiol 26:2371–2377
Sandoval C, Kutscher M, Jayabose S et al (2003) Neurotoxicity of intrathecal methotrexate: MR imaging findings. AJNR Am J Neuroradiol 24:1887–1890
Schulz U, Mann G, Zoubek A et al (1994) Venous thrombosis of cranial sinuses in asparaginase therapy: a case report. Klin Padiatr 206:342–345
Wani NA, Kosar T, Pala NA et al (2010) Sagittal sinus thrombosis due to L-asparaginase. J Pediatr Neurosci 5:32–35
Boukobza M, Crassard I, Bousser MG et al (2009) MR imaging features of isolated cortical vein thrombosis: diagnosis and follow-up. AJNR Am J Neuroradiol 30:344–348
Wheless JW, Carmant L, Bebin M et al (2009) Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 50:195–205
Pearl PL, Vezina LG, Saneto RP et al (2009) Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 50:184–194
Milh M, Villeneuve N, Chapon F et al (2009) Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin. J Child Neurol 24:305–315
Frytak S, Moertel CH (1978) Childs DS neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 88:361–362
Heaney CJ, Campeau NG, Lindell EP (2003) MR imaging and diffusion-weighted imaging changes in metronidazole (Flagyl)-induced cerebellar toxicity. AJNR Am J Neuroradiol 24:1615–1617
Kim E, Na DG, Kim EY et al (2007) MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings. AJNR Am J Neuroradiol 28:1652–1658
McErlean A, Abdalia K, Donoghue V et al (2010) The dentate nucleus in children: normal development and patterns of disease. Pediatr Radiol 40:326–339
Rovira A, Alonso J, Córdoba J (2008) MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol 29:1612–1621
Aschner J, Anderson A, Slaughter J et al (2015) Neuroimaging identifies increased manganese deposition in infants receiving parenteral nutrition. Am J Clin Nutr 102:1482–1489
Jiang J, Shi S, Zhou Q et al (2014) Downregulation of the Wnt/β-catenin signaling pathway is involved in manganese-induced neurotoxicity in rat striatum and PC12 cells. J Neurosci Res 92:783–794
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None
Rights and permissions
About this article
Cite this article
Rossi Espagnet, M.C., Pasquini, L., Napolitano, A. et al. Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature. Pediatr Radiol 47, 633–648 (2017). https://doi.org/10.1007/s00247-016-3750-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00247-016-3750-4